Transgene Biotek Ltd
₹ 6.50
-3.42%
21 Nov
- close price
About
Incorporated in 1990, Transgene Biotek Limited is in the business of Research & Development of Pharmaceutical products. The registered office of the company is in Telangana.[1]
Key Points
- Market Cap ₹ 49.2 Cr.
- Current Price ₹ 6.50
- High / Low ₹ 12.5 / 5.79
- Stock P/E
- Book Value ₹ -0.89
- Dividend Yield 0.00 %
- ROCE -7.26 %
- ROE %
- Face Value ₹ 10.0
Pros
Cons
- Company has low interest coverage ratio.
- Promoter holding is low: 23.6%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Healthcare Industry: Miscellaneous
Loading peers table ...
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 15.01 | 0.97 | 0.30 | 0.18 | 0.28 | 0.12 | 0.07 | 0.00 | 0.17 | 0.09 | 0.06 | 0.23 | 0.21 | |
| 15.78 | 2.79 | 1.81 | 1.32 | 2.84 | 5.12 | 0.75 | 0.87 | 0.70 | 0.55 | 0.68 | 0.83 | 1.07 | |
| Operating Profit | -0.77 | -1.82 | -1.51 | -1.14 | -2.56 | -5.00 | -0.68 | -0.87 | -0.53 | -0.46 | -0.62 | -0.60 | -0.86 |
| OPM % | -5.13% | -187.63% | -503.33% | -633.33% | -914.29% | -4,166.67% | -971.43% | -311.76% | -511.11% | -1,033.33% | -260.87% | -409.52% | |
| 0.00 | -114.37 | 0.01 | 0.17 | 0.66 | 10.27 | 2.04 | 0.18 | 0.27 | 0.21 | 0.18 | 0.18 | 0.78 | |
| Interest | 0.20 | 0.00 | 0.36 | 0.07 | 0.43 | 1.03 | 0.26 | 0.38 | 0.27 | 0.23 | 0.62 | 0.14 | 0.10 |
| Depreciation | 1.02 | 17.22 | 17.18 | 20.50 | 17.53 | 9.89 | 9.89 | 9.90 | 9.91 | 9.92 | 4.95 | 0.09 | 0.08 |
| Profit before tax | -1.99 | -133.41 | -19.04 | -21.54 | -19.86 | -5.65 | -8.79 | -10.97 | -10.44 | -10.40 | -6.01 | -0.65 | -0.26 |
| Tax % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 13.98% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | |
| -1.99 | -133.40 | -19.04 | -21.54 | -19.86 | -6.44 | -8.79 | -10.96 | -10.43 | -10.40 | -6.01 | -0.66 | -0.26 | |
| EPS in Rs | -0.30 | -17.61 | -2.51 | -2.84 | -2.62 | -0.85 | -1.16 | -1.45 | -1.38 | -1.37 | -0.79 | -0.09 | -0.04 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | -13% |
| 5 Years: | 27% |
| 3 Years: | 11% |
| TTM: | 40% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 7% |
| 5 Years: | 14% |
| 3 Years: | 25% |
| TTM: | 92% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 7% |
| 5 Years: | 21% |
| 3 Years: | 19% |
| 1 Year: | -25% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | % |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 65.77 | 75.77 | 75.77 | 75.77 | 75.77 | 75.77 | 75.77 | 75.77 | 75.77 | 75.77 | 75.77 | 75.77 | 75.77 |
| Reserves | 256.27 | 121.41 | 102.38 | 78.89 | -34.48 | -40.92 | -49.71 | -60.67 | -71.11 | -75.97 | -81.98 | -82.64 | -82.51 |
| 22.46 | 13.06 | 14.34 | 15.28 | 16.01 | 9.84 | 9.14 | 10.33 | 11.33 | 12.02 | 13.12 | 14.00 | 13.95 | |
| 24.14 | 139.21 | 137.84 | 123.15 | 30.88 | 31.97 | 31.45 | 31.43 | 31.01 | 25.40 | 25.57 | 25.31 | 24.97 | |
| Total Liabilities | 368.64 | 349.45 | 330.33 | 293.09 | 88.18 | 76.66 | 66.65 | 56.86 | 47.00 | 37.22 | 32.48 | 32.44 | 32.18 |
| 197.80 | 180.58 | 163.40 | 140.95 | 61.16 | 50.97 | 41.10 | 31.20 | 21.32 | 11.40 | 6.45 | 6.36 | 8.18 | |
| CWIP | 0.29 | 0.29 | 0.29 | 0.29 | 2.04 | 1.87 | 1.87 | 1.87 | 1.87 | 1.87 | 1.87 | 1.87 | 0.00 |
| Investments | 92.20 | 92.20 | 92.20 | 92.20 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.11 | 0.11 | 0.10 | 0.10 |
| 78.35 | 76.38 | 74.44 | 59.65 | 24.98 | 23.82 | 23.68 | 23.79 | 23.80 | 23.84 | 24.05 | 24.11 | 23.90 | |
| Total Assets | 368.64 | 349.45 | 330.33 | 293.09 | 88.18 | 76.66 | 66.65 | 56.86 | 47.00 | 37.22 | 32.48 | 32.44 | 32.18 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 99.62 | -2.11 | -0.95 | 0.02 | 0.02 | -0.63 | -1.74 | 0.14 | 0.01 | 0.10 | 0.00 | 0.00 | |
| -101.06 | 1.46 | -0.02 | -0.02 | 0.00 | 3.05 | 1.74 | 0.00 | -0.04 | -0.10 | -0.01 | 0.00 | |
| 1.50 | 0.60 | 0.94 | 0.00 | 0.00 | -2.37 | 0.00 | -0.20 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Cash Flow | 0.06 | -0.05 | -0.02 | 0.00 | 0.02 | 0.05 | 0.00 | -0.06 | -0.02 | 0.00 | -0.01 | 0.00 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 448.16 | 6,867.27 | 19,941.17 | 3,305.28 | 13.04 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Inventory Days | 6.40 | 106.46 | 365.00 | 365.00 | 1,460.00 | 121.67 | 156.43 | |||||
| Days Payable | 437.74 | 25,975.83 | 5,018.75 | 3,528.33 | 13,870.00 | 1,460.00 | 1,199.29 | |||||
| Cash Conversion Cycle | 16.82 | -19,002.11 | 19,941.17 | 3,305.28 | 13.04 | -4,653.75 | -3,163.33 | -1,338.33 | 0.00 | -1,042.86 | 0.00 | |
| Working Capital Days | 53.01 | 692.37 | 1,533.00 | 2,331.94 | -1,733.75 | -21,413.33 | -35,717.86 | -14,277.94 | -4,785.56 | -6,995.83 | -1,634.57 | |
| ROCE % | -0.51% | -6.58% | -9.27% | -11.85% | -17.10% | -14.75% | -25.79% | -34.93% | -49.11% | -73.14% | -57.55% | -7.26% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
15 Nov - Newspaper Advertisement - Notice of 34th Annual General Meeting, Remote E voting information, record date and Book Closure etc.
- Revised Results 13 Nov
- Reg. 34 (1) Annual Report. 12 Nov
-
Intimation Of Book Closure And Cut -Off Date For The 34Th Annual General Meeting Of Transgene Biotek Limited.
Register Of Members And The Share Transfer Books Of The Company Will Remain Closed From Friday The 29Th November 2024 To Thursday The 05Th December, 2024 (Both Days Inclusive) For The Purpose Of 34Th Annual General Meeting Which Is Scheduled To Be Held On Thursday The 05Th December 2024 At IST Through Video Conferencing ('VC') / Other Audio Visual Means ('OAVM') At 10.00 A.M. (IST).
12 Nov - Book closure and cut-off date for AGM.
- Outcome Of Board Meeting. This Has Reference To Our Letter Dated 03Rd November 2024. At The Meeting Of The Board Of The Company Held On Tuesday 12Th November 2024, The Following Decisions Were Taken: 1. Un- Audited Financial Results (Standalone And Consolidated) For The Quarter And Half Year Ended 30.09.2024. (Attached). 2.Limited Review Report (Standalone And Consolidated) For The Quarter And Half Year Ended 30.09.2024. (Attached). 12 Nov
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
Business Expertise:[1]
Company is in production and oral formulation of different proteins using TrabiORAL technology
a) Oncology[2]
b) Auto Immunity[3]
c) Drug Delivery[4]
d) Biogenerics[5]